These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

432 related articles for article (PubMed ID: 26404259)

  • 1. PI3K and AKT: Unfaithful Partners in Cancer.
    Faes S; Dormond O
    Int J Mol Sci; 2015 Sep; 16(9):21138-52. PubMed ID: 26404259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
    Polivka J; Janku F
    Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The PI3K/AKT Pathway as a Target for Cancer Treatment.
    Mayer IA; Arteaga CL
    Annu Rev Med; 2016; 67():11-28. PubMed ID: 26473415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New development of inhibitors targeting the PI3K/AKT/mTOR pathway in personalized treatment of non-small-cell lung cancer.
    Sun Z; Wang Z; Liu X; Wang D
    Anticancer Drugs; 2015 Jan; 26(1):1-14. PubMed ID: 25304988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting PI3 kinase in cancer.
    Bauer TM; Patel MR; Infante JR
    Pharmacol Ther; 2015 Feb; 146():53-60. PubMed ID: 25240910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quinazoline based small molecule exerts potent tumour suppressive properties by inhibiting PI3K/Akt/FoxO3a signalling in experimental colon cancer.
    Qazi AK; Hussain A; Khan S; Aga MA; Behl A; Ali S; Singh SK; Taneja SC; Shah BA; Saxena AK; Mondhe DM; Hamid A
    Cancer Lett; 2015 Apr; 359(1):47-56. PubMed ID: 25554016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the PI3K/Akt signaling pathway in gastric carcinoma: A reality for personalized medicine?
    Singh SS; Yap WN; Arfuso F; Kar S; Wang C; Cai W; Dharmarajan AM; Sethi G; Kumar AP
    World J Gastroenterol; 2015 Nov; 21(43):12261-73. PubMed ID: 26604635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alisertib induces cell cycle arrest and autophagy and suppresses epithelial-to-mesenchymal transition involving PI3K/Akt/mTOR and sirtuin 1-mediated signaling pathways in human pancreatic cancer cells.
    Wang F; Li H; Yan XG; Zhou ZW; Yi ZG; He ZX; Pan ST; Yang YX; Wang ZZ; Zhang X; Yang T; Qiu JX; Zhou SF
    Drug Des Devel Ther; 2015; 9():575-601. PubMed ID: 25632225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [PI3K-AKT-mTOR pathway inhibitors].
    Cortot A; Armand JP; Soria JC
    Bull Cancer; 2006 Jan; 93(1):19-26. PubMed ID: 16455502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors.
    Andersen JN; Sathyanarayanan S; Di Bacco A; Chi A; Zhang T; Chen AH; Dolinski B; Kraus M; Roberts B; Arthur W; Klinghoffer RA; Gargano D; Li L; Feldman I; Lynch B; Rush J; Hendrickson RC; Blume-Jensen P; Paweletz CP
    Sci Transl Med; 2010 Aug; 2(43):43ra55. PubMed ID: 20686178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer.
    Bitting RL; Armstrong AJ
    Endocr Relat Cancer; 2013 Jun; 20(3):R83-99. PubMed ID: 23456430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maximising the potential of AKT inhibitors as anti-cancer treatments.
    Brown JS; Banerji U
    Pharmacol Ther; 2017 Apr; 172():101-115. PubMed ID: 27919797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER2 expression and PI3K-Akt pathway alterations in gastric cancer.
    Sukawa Y; Yamamoto H; Nosho K; Ito M; Igarashi H; Naito T; Mitsuhashi K; Matsunaga Y; Takahashi T; Mikami M; Adachi Y; Suzuki H; Shinomura Y
    Digestion; 2014; 89(1):12-7. PubMed ID: 24458107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of the PI3K-AKT pathway in melanoma.
    Davies MA
    Cancer J; 2012; 18(2):142-7. PubMed ID: 22453015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diallyl trisulfide-induced apoptosis of bladder cancer cells is caspase-dependent and regulated by PI3K/Akt and JNK pathways.
    Shin DY; Kim GY; Hwang HJ; Kim WJ; Choi YH
    Environ Toxicol Pharmacol; 2014 Jan; 37(1):74-83. PubMed ID: 24309133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphatidylinositol 3-kinase/Akt signaling as a key mediator of tumor cell responsiveness to radiation.
    Toulany M; Rodemann HP
    Semin Cancer Biol; 2015 Dec; 35():180-90. PubMed ID: 26192967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Twist promotes reprogramming of glucose metabolism in breast cancer cells through PI3K/AKT and p53 signaling pathways.
    Yang L; Hou Y; Yuan J; Tang S; Zhang H; Zhu Q; Du YE; Zhou M; Wen S; Xu L; Tang X; Cui X; Liu M
    Oncotarget; 2015 Sep; 6(28):25755-69. PubMed ID: 26342198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The phosphatidylinositol 3-kinase/Akt and c-Jun N-terminal kinase signaling in cancer: Alliance or contradiction? (Review).
    Zhao HF; Wang J; Tony To SS
    Int J Oncol; 2015 Aug; 47(2):429-36. PubMed ID: 26082006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Danusertib, a potent pan-Aurora kinase and ABL kinase inhibitor, induces cell cycle arrest and programmed cell death and inhibits epithelial to mesenchymal transition involving the PI3K/Akt/mTOR-mediated signaling pathway in human gastric cancer AGS and NCI-N78 cells.
    Yuan CX; Zhou ZW; Yang YX; He ZX; Zhang X; Wang D; Yang T; Pan SY; Chen XW; Zhou SF
    Drug Des Devel Ther; 2015; 9():1293-318. PubMed ID: 25767376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Will PI3K pathway inhibitors be effective as single agents in patients with cancer?
    Garrett JT; Chakrabarty A; Arteaga CL
    Oncotarget; 2011 Dec; 2(12):1314-21. PubMed ID: 22248929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.